Does Kura Oncology (NASDAQ:KURA) Have A Healthy Balance Sheet?
Barclays Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $32
BTIG Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $32
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $32
Express News | Kura Oncology Inc: Ziftomenib Induces Insulin Production
Express News | Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in Diabetes
JMP Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $32
BofA Securities Maintains Kura Oncology(KURA.US) With Buy Rating
Express News | Kura Oncology Inc : BofA Global Research Raises Price Objective to $35 From $33
Dynavax, Bloomin Brands, and Premier Are the Most Shorted Small-cap Stock in May - Hazeltree Report
Kura Oncology(KURA.US) Officer Sells US$57,916.24 in Common Stock
Investor Enthusiasm Soars for Kura Oncology (NASDAQ:KURA)
Buy Rating Affirmed for Kura Oncology Amidst Promising Ziftomenib Trials and Strategic Advantages
Kura Oncology Enrolls 85 Patients in Ziftomenib Trial for Leukemia Drug
Analysts Offer Insights on Healthcare Companies: Kura Oncology (KURA) and Tourmaline Bio (TRML)
Express News | Kura Oncology Inc: Topline Data Expected in Early 2025
Express News | Kura Oncology Inc: Completes Enrollment in Registration-Directed Trial of Ziftomenib in Npm1-Mutant Aml
Estimating The Intrinsic Value Of Kura Oncology, Inc. (NASDAQ:KURA)
Express News | JMP Securities Reiterates Market Outperform on Kura Oncology, Maintains $32 Price Target
Analysts Are Bullish on These Healthcare Stocks: Relay Therapeutics (RLAY), Kura Oncology (KURA)